| ID Source | ID |
|---|---|
| PubMed CID | 135435111 |
| SCHEMBL ID | 455853 |
| MeSH ID | M0143179 |
| Synonym |
|---|
| 1h-purine-6,8-dione, 2-amino-7,9-dihydro-7-methyl-9-b-d-ribofuranosyl- |
| 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-7-methyl-1h-purine-6,8-dione |
| 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methyl-3h-purine-6,8-dione |
| 7-methyl-8-oxoguanosine |
| 7-methyl-8-oxo-7,8-dihydroguanosine |
| 7-me-8-og |
| nsc 127522 |
| 2-amino-7-methyl-9-(beta-ribofuranosyl)-1h,9h-purine-6,8-dione |
| guanosine, 7,8-dihydro-7-methyl-8-oxo- |
| SCHEMBL455853 |
| 2-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-methyl-3h-purine-6,8(7h,9h)-dione |
| STARBLD0002225 |
| Excerpt | Reference |
|---|---|
| " As an adjuvant for in vitro antibody responses, however, 7m8oGuo achieves the same degree of immunoenhancement as 8MGuo but at approximately 10-fold lower concentrations, that is, the dose-response profile has been shifted to the left." | ( Distinct effects of dual substitution on inductive and differentiative activities of C8-substituted guanine ribonucleosides. Goodman, MG; Hennen, WJ, 1986) |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (11.11%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||